Novel opportunities for thymidylate metabolism as a therapeutic target.
For over 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) has remained the central agent in therapeutic regimens employed in the treatment of colorectal cancer and is frequently combined with the DNA-damaging agents oxaliplatin and irinotecan, increasing response rates and improving overall survival. However, many patients will derive little or no benefit from treatment, highlighting the need to identify novel therapeutic targets to improve the efficacy of current 5-FU-based chemotherapeutic strategies. dUTP nucleotidohydrolase (dUTPase) catalyzes the hydrolysis of dUTP to dUMP and PPi, providing substrate for thymidylate synthase (TS) and DNA synthesis and repair. Although dUTP is a normal intermediate in DNA synthesis, its accumulation and misincorporation into DNA as uracil is lethal. Importantly, uracil misincorporation represents an important mechanism of cytotoxicity induced by the TS-targeted class of chemotherapeutic agents including 5-FU. A growing body of evidence suggests that dUTPase is an important mediator of response to TS-targeted agents. In this article, we present further evidence showing that elevated expression of dUTPase can protect breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU. We therefore report the implementation of in silico drug development techniques to identify and develop small-molecule inhibitors of dUTPase. As 5-FU and the oral 5-FU prodrug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small-molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents.
Wilson
Peter M
PM
Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Room 5322, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA.
Fazzone
William
W
LaBonte
Melissa J
MJ
Deng
Jinxia
J
Neamati
Nouri
N
Ladner
Robert D
RD
D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology; D045744:Cell Line, Tumor; D019295:Computational Biology; D004249:DNA Damage; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D011755:Pyrophosphatases / Q000037:antagonists & inhibitors*; D015203:Reproducibility of Results; D013936:Thymidine / Q000378:metabolism*
D000970:Antineoplastic Agents; D011755:Pyrophosphatases; C020020:dUTP pyrophosphatase; D005472:Fluorouracil; D013936:Thymidine
Mol Pharmacol. 1980 Nov;18(3):513-20
6110169
J Clin Oncol. 2004 Feb 1;22(3):529-36
14752076
Int J Cancer. 1999 Dec 22;84(6):614-7
10567908
Clin Colorectal Cancer. 2006 Nov;6(4):261-4
17241510
Curr Top Med Chem. 2002 Mar;2(3):211-27
11944817
J Clin Oncol. 1999 Mar;17(3):1061-70
10071301
Clin Cancer Res. 2000 Apr;6(4):1322-7
10778957
Structure. 1996 Sep 15;4(9):1077-92
8805593
Biochem Pharmacol. 1997 Sep 1;54(5):635-8
9337081
J Clin Oncol. 2001 Nov 1;19(21):4097-106
11689577
Nature. 1957 Mar 30;179(4561):663-6
13418758
Cancer Res. 2002 Sep 1;62(17):4909-15
12208740
Pharmacogenetics. 2004 May;14(5):319-27
15115918
Pharmacogenomics J. 2001;1(1):65-70
11913730
Cancer Res. 2000 Jul 1;60(13):3493-503
10910061
Lancet. 2000 Mar 25;355(9209):1041-7
10744089
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
Cancer Res. 2003 Jun 1;63(11):2898-904
12782596
J Mol Biol. 1997 Apr 4;267(3):727-48
9126849
Nucleic Acids Symp Ser. 1995;(34):77-8
8841560
Cancer Res. 1991 May 1;51(9):2346-52
2015598
Clin Cancer Res. 1998 May;4(5):1243-50
9607583
J Clin Oncol. 2004 Jan 15;22(2):229-37
14657227
Br J Cancer. 2000 Sep;83(6):792-9
10952785
Eur J Cancer. 1998 Jul;34(8):1274-81
9849491
Cancer Res. 1995 Apr 1;55(7):1407-12
7882343
J Clin Oncol. 2002 Apr 1;20(7):1721-8
11919227
Cancer Res. 2007 Feb 1;67(3):940-5
17283124
J Bacteriol. 1988 Mar;170(3):1069-75
2830228
Nat Rev Cancer. 2003 May;3(5):330-8
12724731
N Engl J Med. 2006 Dec 28;355(26):2733-43
17192538
Mol Pharmacol. 2004 Sep;66(3):620-6
15322254
Anal Biochem. 1989 Aug 1;180(2):222-6
2554751
J Clin Oncol. 2000 Jan;18(1):136-47
10623704
Cancer Res. 1994 May 1;54(9):2296-8
8162567
J Clin Oncol. 2007 Nov 20;25(33):5210-7
17968020
Mol Pharmacol. 1982 Jan;21(1):211-6
6215571
Clin Pharmacokinet. 1989 Apr;16(4):215-37
2656050